NetworkNewsBreaks – Pulmatrix, Inc. (NASDAQ: PULM) Obtains Key U.S. Patent for PUR0200 to Treat COPD
Pulmatrix (NASDAQ: PULM) said today that it has received a key patent in the United States for its lead drug candidate, PUR0200, which is intended to treat chronic obstructive pulmonary diseases (COPD). PUR0200 is an inhaled drug made by combining Pulmatrix's technology platform with tiotropium bromide. The patent provides the company with intellectual property protection for the drug until 2033. The company is currently developing PUR0200 in both Europe and the United States, following regulatory pathways that offer faster approvals and decreased costs. "This new patent is another step forward to bringing PUR0200 to market—and to be able to offer…